SEC Form 4 · accession 0001451612-26-000012
Kymera Therapeutics, Inc. · KYMR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Bruce Booth
Director
Period of report
Jun 17, 2026
Accepted (ET)
Jun 22, 2026 · 9:02 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001815442
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2,F3 | Jun 22, 2026 | S | 18,313 | $103.42 | D | 3,472,340 | I | See footnote |
| Common StockF4,F3 | Jun 22, 2026 | S | 9,584 | $104.38 | D | 3,462,756 | I | See footnote |
| Common StockF2,F5 | Jun 22, 2026 | S | 2,560 | $103.42 | D | 615,103 | I | See footnote |
| Common StockF4,F5 | Jun 22, 2026 | S | 1,341 | $104.38 | D | 613,762 | I | See footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $103.0194 to $103.945 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold each separate price within the ranges set forth in footnotes (2) and (4).
- F3These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any.
- F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $104.11 to $104.8748 inclusive.
- F5The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF, except to the extent of his pecuniary interest therein, if any.
Remarks
Due to the 30 line limitation in Table I, this report is being filed across two forms. This is the second of two filings.